What we are studying
The Connect research study will look at an experimental drug that is being developed for Alzheimer’s disease (AD). “Experimental” means that the study drug has not been approved by the US Food and Drug administration for the treatment of AD.
The purpose of this research study is to determine whether it is safe and effective in slowing decline in brain metabolism, memory and daily function in people with Alzheimer’s disease (AD).
Screening Visit 1 $25.00
Screening Visit 1a (MRI Scan) $25.00
Screening Visit 1b (PET Scan) $50.00
Baseline Visit 2 $120.00
Baseline Lumbar Puncture (Optional) $100.00
Visits 3, 4, 5, 6, 8, 10 & 12 $40.00 per completed study visit ($280)